R&D

May, 2020

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.

Reddy TP, Choi DS, Anselme AC, Qian W, Chen W, Lantto J, Horak ID, Kragh M, Chang JC, Rosato RR.
Breast Cancer Res. 2020 May 15;22(1):48. doi: 10.1186/s13058-020-01280-z.
November, 2019

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR.
J Pharmacokinet Pharmacodyn. 2020 Feb;47(1):5-18. doi: 10.1007/s10928-019-09663-2. Epub 2019 Nov 2
October, 2019

CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.

Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, Lantto J, Horak ID, Kragh M, Nielsen CH, Kjaer A.
Theranostics. 2019 Oct 18;9(26):8221-8238. doi: 10.7150/thno.37513. eCollection 2019.
May, 2019

Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform

Gjetting T, Gad M, Fröhlich C, Lindsted T, Melander MC, Bhatia VK, Grandal MM, Dietrich N, Uhlenbrock F, Galler GR, Strandh M, Lantto J, Bouquin T, Horak ID, Kragh M, Pedersen MW, Koefoed K.
MAbs. 2019 May 3:1-15. doi: 10.1080/19420862.2019.1596514
February, 2018

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor

im HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY.
Int J Cancer. 2018 Feb 13
February, 2018

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

Clara Montagut, MD, Guillem Argilés, MD, Fortunato Ciardiello, MD, Thomas T. Poulsen, PhD, Rodrigo Dienstmann, MD, Michael Kragh, PhD, Scott Kopetz, MD, Trine Lindsted, PhD, Cliff Ding, PhD, Joana Vidal, MD, Jenifer Clausell-Tormos, PhD, Giulia Siravegna, PhD, Francisco J. Sánchez-Martín, PhD, Klaus Koefoed, PhD, Mikkel W. Pedersen, PhD, Michael M. Grandal, PhD, Mikhail Dvorkin, MD, Lucjan Wyrwicz, MD, Ana Rovira, PhD, Antonio Cubillo, MD, Ramon Salazar, MD, Françoise Desseigne, MD, Cristina Nadal, MD, Joan Albanell, MD, Vittorina Zagonel, MD, Salvatore Siena, MD, Guglielmo Fumi, MD, Giuseppe Rospo, PhD, Paul Nadler, MD, Ivan D. Horak, MD, Alberto Bardelli, PhD, Josep Tabernero, MD
JAMA Oncol. Published online February 8, 2018. doi:10.1001/jamaoncol.2017.5245
December, 2017

Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.

Grandal MM, Havrylov S, Poulsen TT, Koefoed K, Dahlman A, Galler GR, Conrotto P, Collins S, Eriksen KW, Kaufman D, Woude GFV, Jacobsen HJ, Horak ID, Kragh M, Lantto J, Bouquin T, Park M, Pedersen MW
Mol Cancer Ther. 2017 Dec;16(12):2780-2791
November, 2017

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz LJ. Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.
J Natl Cancer Inst. 2017 Nov 1;109(11)